stoxline Quote Chart Rank Option Currency Glossary
  
Ascendis Pharma A/S (ASND)
156.245  0.055 (0.04%)    02-19 14:24
Open: 155
High: 156.56
Volume: 496,248
  
Pre. Close: 156.19
Low: 150.09
Market Cap: 9,350(M)
Technical analysis
2025-02-19 1:48:41 PM
Short term     
Mid term     
Targets 6-month :  183.8 1-year :  214.68
Resists First :  157.36 Second :  183.8
Pivot price 130.97
Supports First :  133.05 Second :  118.02
MAs MA(5) :  144.81 MA(20) :  130.16
MA(100) :  131.95 MA(250) :  135.44
MACD MACD :  3.9 Signal :  0
%K %D K(14,3) :  93 D(3) :  86
RSI RSI(14): 70.7
52-week High :  161 Low :  111.08
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ASND ] has closed above the upper band by 0.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 176.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 157.46 - 157.93 157.93 - 158.45
Low: 143.66 - 144.2 144.2 - 144.8
Close: 155.18 - 156.04 156.04 - 157.01
Company Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Headline News

Wed, 19 Feb 2025
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $260.00 at Evercore ISI - MarketBeat

Tue, 18 Feb 2025
Rice Hall James & Associates LLC Has $22.56 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat

Sun, 16 Feb 2025
Ascendis Pharma A/S (NASDAQ:ASND) Given New $168.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Sun, 16 Feb 2025
Ascendis Pharma A/S (NASDAQ:ASND) Issues Earnings Results - MarketBeat

Sat, 15 Feb 2025
Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results: Here's What Analysts Are Forecasting For This Year - Simply Wall St

Thu, 13 Feb 2025
Ascendis Pharma A/S Earnings Call Highlights Growth and Challenges - TipRanks

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 60 (M)
Shares Float 59 (M)
Held by Insiders 0.7 (%)
Held by Institutions 110.6 (%)
Shares Short 3,290 (K)
Shares Short P.Month 3,420 (K)
Stock Financials
EPS -6.79
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.77
Profit Margin -104 %
Operating Margin 0.2 %
Return on Assets (ttm) -17.4 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 26.2 %
Gross Profit (p.s.) 5.33
Sales Per Share 6.07
EBITDA (p.s.) -4.58
Qtrly Earnings Growth 0 %
Operating Cash Flow -306 (M)
Levered Free Cash Flow -200 (M)
Stock Valuations
PE Ratio -22.86
PEG Ratio 0
Price to Book value -87.68
Price to Sales 25.53
Price to Cash Flow -30.33
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android